Skip to main content
SpringerLink
Log in

What are the Real Lessons from Vioxx®?

  • Editorial
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Kermode-Scott B. Agencies ‘failed miserably’ over COX inhibitor. BMJ 2005; 330: 113

    Article  PubMed  Google Scholar 

  2. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004 Dec 4; 364(9450): 2021–9

    Article  PubMed  CAS  Google Scholar 

  3. FDA Advisory Committee briefing document: VIOXX gastrointestinal safety, NDA 21-042, s007, 2001 Feb 8 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_03_med.doc [Accessed 2005 Jun 30]

  4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000 Nov 23; 343(21): 1520–8

    Article  PubMed  CAS  Google Scholar 

  5. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002 Oct 5; 360(9339): 1071–3

    Article  PubMed  CAS  Google Scholar 

  6. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002 Mar 21; 89(6A): 3D–9D

    Article  PubMed  CAS  Google Scholar 

  7. Wiholm BE. Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database. Curr Med Res Opin 2001; 1(3): 210–6

    Google Scholar 

  8. Zhao SZ, Reynolds MW, Lejkowith J, et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23(9): 1478–91

    Article  PubMed  CAS  Google Scholar 

  9. van Grootheest AC, Edwards IR. Labelling and ‘Dear Doctor’ letters: are they noncommittal? Drug Saf 2002; 25(15): 1051–5

    Article  PubMed  Google Scholar 

  10. Edwards IR. Dextropropoxyphene. N Z Med J 1985; 98(775): 201

    PubMed  CAS  Google Scholar 

  11. European Commission, Enterprise and Industry, Pharmaceuticals Unit. Pharmacovigilance: medicinal products for human use and veterinary medicinal products, vol. 9 [online]. Available from URL: http://www.pharmacos.eudra.org/F2/eudralex/vol-9/pdfVol9_07-2004.pdf [Accessed 2004 Jul 1]

  12. Fucik H, Edwards IR. Impact and credibility of the WHO adverse reaction signals. Drug Inf J 1996; 30(2): 461–4

    Article  Google Scholar 

  13. Stahl M, Edwards IR, Bowring G, et al. Assessing the impact of drug safety signals from the WHO database presented in ‘signal’: results from a questionnaire of national pharmacovigilance centres. Drug Saf 2003; 26(10): 721–7

    Article  PubMed  Google Scholar 

  14. Uhl K, Honig P. Risk management of marketed drugs: FDA and the interface with the practice of medicine. Pharmacoepidemiol Drug Saf 2001 May; 10(3): 205–8

    Article  PubMed  CAS  Google Scholar 

  15. Bowdler J. Effective communications in pharmacovigilance. Birmingham: W Lake Ltd, 1996

    Google Scholar 

  16. Bowdler J. Dialogue in pharmacovigilance. Uppsala: The Uppsala Monitoring Centre, 2002

    Google Scholar 

Download references

Acknowledgements

This paper is adapted from an original with the same title in ‘Uppsala Reports’ (No. 29), the newsletter of the WHO Foundation Collaborating Centre and the author is indebted to Dr Kees van Grootheest, Professor Chalbi Belkahia and Dr Roselie A. Bright, who contributed to the original.

No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. WHO Foundation Collaborating Centre for International Drug Monitoring, Stora Torget 3, 75230, Uppsala, Sweden

    I. Ralph Edwards

Authors
  1. I. Ralph Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Ralph Edwards.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edwards, I.R. What are the Real Lessons from Vioxx®?. Drug-Safety 28, 651–658 (2005). https://doi.org/10.2165/00002018-200528080-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200528080-00001

Search

Navigation